M. Soheilipour, Amir Aria, M. Momenzadeh, Elham Tabesh, Peyman Adibi Sedeh
Introduction: Ineffective esophageal motility (IEM) is an esophageal motility disorder (EMD) and the most prevalent abnormality routinely observed in esophageal manometry. Objectives: In this study, we investigated the clinical characteristics of IEM patients and the effects of proton pump inhibitors (PPI) and surgical treatments on their conditions. Patients and Methods: This cross-sectional study was conducted in Isfahan in 2019-2020 on 40 patients diagnosed with IEM. We collected patient demographic information (age, gender, previous medical history, medications, and duration of the current problem) and clinical manifestations (clinical symptoms of patients including dysphagia, heartburn, food and acid regurgitation, chest pain and belching) prior to and following PPI or surgical treatment. Results: Approximately 65% of patients presented with dysphagia and heartburn, 55% had food and acid regurgitation, 47.5% had belching, and 55% had chest pain. Post-treatment findings revealed that only the recurrence of food and acid regurgitation was significantly lower in the PPI treatment group than in the surgical group. Only dysphagia severity was statistically significant in the surgical group compared to other symptoms (P=0.042). In the PPI group, the severity of heartburn (P=0.007), dysphagia (P<0.001), food and acid regurgitation (P=0.007), and chest pain (P=0.027) decreased significantly compared to baseline. Conclusion: This study showed that the common clinical manifestations of IEM were dysphagia, heartburn, food and acid regurgitation, and belching. Moreover, treatment with PPI resulted in more significant improvements than surgical treatment.
{"title":"Clinical features, endoscopic and manometric findings in patients with ineffective esophageal motility","authors":"M. Soheilipour, Amir Aria, M. Momenzadeh, Elham Tabesh, Peyman Adibi Sedeh","doi":"10.34172/ipp.2023.39451","DOIUrl":"https://doi.org/10.34172/ipp.2023.39451","url":null,"abstract":"Introduction: Ineffective esophageal motility (IEM) is an esophageal motility disorder (EMD) and the most prevalent abnormality routinely observed in esophageal manometry. Objectives: In this study, we investigated the clinical characteristics of IEM patients and the effects of proton pump inhibitors (PPI) and surgical treatments on their conditions. Patients and Methods: This cross-sectional study was conducted in Isfahan in 2019-2020 on 40 patients diagnosed with IEM. We collected patient demographic information (age, gender, previous medical history, medications, and duration of the current problem) and clinical manifestations (clinical symptoms of patients including dysphagia, heartburn, food and acid regurgitation, chest pain and belching) prior to and following PPI or surgical treatment. Results: Approximately 65% of patients presented with dysphagia and heartburn, 55% had food and acid regurgitation, 47.5% had belching, and 55% had chest pain. Post-treatment findings revealed that only the recurrence of food and acid regurgitation was significantly lower in the PPI treatment group than in the surgical group. Only dysphagia severity was statistically significant in the surgical group compared to other symptoms (P=0.042). In the PPI group, the severity of heartburn (P=0.007), dysphagia (P<0.001), food and acid regurgitation (P=0.007), and chest pain (P=0.027) decreased significantly compared to baseline. Conclusion: This study showed that the common clinical manifestations of IEM were dysphagia, heartburn, food and acid regurgitation, and belching. Moreover, treatment with PPI resulted in more significant improvements than surgical treatment.","PeriodicalId":13454,"journal":{"name":"Immunopathologia Persa","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2023-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44041140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction: Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the second leading cause of cancer-related death, worldwide. Objectives: This study aimed to evaluate the CD133 expression rate in colon cancers and determine its relationship with colon cancer prognosis. Patients and Methods: This cross-sectional study was conducted in AL-Zahra hospital in Isfahan from April 2008 to April 2014 on 80 patients with CRC. In this study demographic profile such as age and gender, clinicopathologic profile including tumor grade, size, stage, metastasis, 5-year survival and their relation with CD133 expression in form of diffuse, weakly and negative were investigated. Results: From the 80 investigated patients, 47 (58.8%) were male and rest were female. The most common type of CD133 was diffuse type with the 43.8% of cases. Mean age of patients was 61.4 ±14.12 years. This study showed a significant difference between type of CD133 in regards of tumour size (from 23.11 mm in negative cases to 38.85 in weakly cases, P = 0.047). Moreover, the 5-year survival in the three groups of CD133 were significantly different (from 22.54 months in diffuse to 34.42 months in negative cases, P = 0.025). Conclusion: CD133 may be considered as an important tumor marker and a prognostic and diagnostic marker, as well as a therapeutic approach in patients with CRC.
{"title":"Evaluation of CD133 expression rate in colon cancers with immunohistochemistry method and its relationship with colon cancer prognosis","authors":"MH. Sanei, Tina Foodeh, M. Sanei","doi":"10.34172/ipp.2023.35458","DOIUrl":"https://doi.org/10.34172/ipp.2023.35458","url":null,"abstract":"Introduction: Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the second leading cause of cancer-related death, worldwide. Objectives: This study aimed to evaluate the CD133 expression rate in colon cancers and determine its relationship with colon cancer prognosis. Patients and Methods: This cross-sectional study was conducted in AL-Zahra hospital in Isfahan from April 2008 to April 2014 on 80 patients with CRC. In this study demographic profile such as age and gender, clinicopathologic profile including tumor grade, size, stage, metastasis, 5-year survival and their relation with CD133 expression in form of diffuse, weakly and negative were investigated. Results: From the 80 investigated patients, 47 (58.8%) were male and rest were female. The most common type of CD133 was diffuse type with the 43.8% of cases. Mean age of patients was 61.4 ±14.12 years. This study showed a significant difference between type of CD133 in regards of tumour size (from 23.11 mm in negative cases to 38.85 in weakly cases, P = 0.047). Moreover, the 5-year survival in the three groups of CD133 were significantly different (from 22.54 months in diffuse to 34.42 months in negative cases, P = 0.025). Conclusion: CD133 may be considered as an important tumor marker and a prognostic and diagnostic marker, as well as a therapeutic approach in patients with CRC.","PeriodicalId":13454,"journal":{"name":"Immunopathologia Persa","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2023-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43097763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Fakhri, H. Azadeh, A. Jokar, M. Moosazadeh, H. Fakheri, Melina Ramezanpour
Introduction: Rheumatoid arthritis is a chronic autoimmune disease with numerous side effects. Since long ago, the impact of fish consumption on treating this disease has been of researchers’ interest. Hence, this study aims to examine the relationship between fish consumption and the risk of rheumatoid arthritis through a systematic review and a meta-analysis method. Materials and Methods: For this meta-analysis to reach the research related to the case study, the following databases: PubMed, Scopus, Web of Science, Cochrane, and the Google Scholar search engine were conducted. The data were analyzed using the STATA 14, and the significance level of the tests was P <0.05. Results: There were 2166980 people (20218 cases and 2146762 controls) in this case study, and the age range of the patients was between 18 and 89. The studies were published between 1991 and 2022 and estimated the odds ratio (OR) of fish consumption and rheumatoid arthritis as (OR =0.83; 95% CI: 0.78, 0.89). This measure was (OR =0.79; 95% CI: 0.72, 0.87) in six case-control studies and (OR =0.86; 95% CI: 0.78, 0.94) in 7 cohort studies. In addition, the effect of fish consumption on reducing the rheumatoid arthritis development was more in people who had consumed fish 2 or less than 2 times a week compared to people who consumed fish more than 2 times every week. Conclusion: Fish consumption reduces the rheumatoid arthritis extension; therefore, these patients are advised to include fish in their diet.
简介：类风湿性关节炎是一种慢性自身免疫性疾病，有许多副作用。很久以前，研究人员就对食用鱼类对治疗这种疾病的影响感兴趣。因此，本研究旨在通过系统综述和荟萃分析方法来检验鱼类消费与类风湿性关节炎风险之间的关系。材料和方法：为了达到与案例研究相关的研究，本荟萃分析使用了以下数据库：PubMed、Scopus、Web of Science、Cochrane和Google Scholar搜索引擎。使用STATA14对数据进行分析，测试的显著性水平为P<0.05。结果：本病例研究共有2166980人（20218例和2146762例对照），患者年龄范围在18至89岁之间。这些研究发表于1991年至2022年，估计鱼类消费与类风湿性关节炎的比值比（OR）为（OR=0.83；95%CI:0.78，0.89）。在6项病例对照研究中，这一指标为（OR=779；95%CI:0.72，0.87），在7项队列研究中为（OR=886；95%CI:0.98，0.94）。此外，与每周食用鱼类超过2次的人相比，每周食用鱼类2次或2次以下的人食用鱼类对减少类风湿性关节炎发展的影响更大。结论：食用鱼类可减少类风湿性关节炎的扩展；因此，建议这些患者在饮食中加入鱼类。
{"title":"The relationship between fish consumption and Rheumatoid Arthritis: a systematic review and meta-analysis","authors":"M. Fakhri, H. Azadeh, A. Jokar, M. Moosazadeh, H. Fakheri, Melina Ramezanpour","doi":"10.34172/ipp.2023.36452","DOIUrl":"https://doi.org/10.34172/ipp.2023.36452","url":null,"abstract":"Introduction: Rheumatoid arthritis is a chronic autoimmune disease with numerous side effects. Since long ago, the impact of fish consumption on treating this disease has been of researchers’ interest. Hence, this study aims to examine the relationship between fish consumption and the risk of rheumatoid arthritis through a systematic review and a meta-analysis method. Materials and Methods: For this meta-analysis to reach the research related to the case study, the following databases: PubMed, Scopus, Web of Science, Cochrane, and the Google Scholar search engine were conducted. The data were analyzed using the STATA 14, and the significance level of the tests was P <0.05. Results: There were 2166980 people (20218 cases and 2146762 controls) in this case study, and the age range of the patients was between 18 and 89. The studies were published between 1991 and 2022 and estimated the odds ratio (OR) of fish consumption and rheumatoid arthritis as (OR =0.83; 95% CI: 0.78, 0.89). This measure was (OR =0.79; 95% CI: 0.72, 0.87) in six case-control studies and (OR =0.86; 95% CI: 0.78, 0.94) in 7 cohort studies. In addition, the effect of fish consumption on reducing the rheumatoid arthritis development was more in people who had consumed fish 2 or less than 2 times a week compared to people who consumed fish more than 2 times every week. Conclusion: Fish consumption reduces the rheumatoid arthritis extension; therefore, these patients are advised to include fish in their diet.","PeriodicalId":13454,"journal":{"name":"Immunopathologia Persa","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2023-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43909441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hanieh Raji, S. Borsi, Z. Mehraban, Sahar Azizi Moghadam
Introduction: Long-term pulmonary consequences of coronavirus disease 2019 (COVID-19) are unknown. Objectives: The aim of this study was the clinical and radiologic consequences and pulmonary function test in the cured COVID-19 patients in a three-month follow-up. Patients and Methods: Patients with laboratory-confirmed COVID-19 infection by a reverse transcription polymerase chain reaction (RT-PCR) assay were recruited in this prospective descriptive epidemiological study. Computerized tomography (CT) scan and blood oxygen measurement were performed before and three months after discharge for all the patients. Spirometry test and 6-minute walk test (6MWT) were conducted to determine the levels of dyspnea and persistent respiratory symptoms. Results: Eighty patients were recruited in this study. At the 3-month follow-up, oxygen saturation was higher than the time of discharge from the hospital. Chest CT scan showed abnormal results in 66.3% of patients. The pulmonary function test results indicated that only 27 (35.75%) of patients had abnormal test. The median distance in the 6MWT was 325 meters (interquartile range, 96-480 m). Conclusion: Follow-up of COVID-19 patients revealed radiological abnormalities in most cured COVID-19 patients, indicating the need for more extended follow-up periods for investigating the long-term consequences of COVID-19.
{"title":"Clinical, radiological outcomes and pulmonary function tests in patients recovered from COVID-19 in a three-month follow-up","authors":"Hanieh Raji, S. Borsi, Z. Mehraban, Sahar Azizi Moghadam","doi":"10.34172/ipp.2023.31362","DOIUrl":"https://doi.org/10.34172/ipp.2023.31362","url":null,"abstract":"Introduction: Long-term pulmonary consequences of coronavirus disease 2019 (COVID-19) are unknown. Objectives: The aim of this study was the clinical and radiologic consequences and pulmonary function test in the cured COVID-19 patients in a three-month follow-up. Patients and Methods: Patients with laboratory-confirmed COVID-19 infection by a reverse transcription polymerase chain reaction (RT-PCR) assay were recruited in this prospective descriptive epidemiological study. Computerized tomography (CT) scan and blood oxygen measurement were performed before and three months after discharge for all the patients. Spirometry test and 6-minute walk test (6MWT) were conducted to determine the levels of dyspnea and persistent respiratory symptoms. Results: Eighty patients were recruited in this study. At the 3-month follow-up, oxygen saturation was higher than the time of discharge from the hospital. Chest CT scan showed abnormal results in 66.3% of patients. The pulmonary function test results indicated that only 27 (35.75%) of patients had abnormal test. The median distance in the 6MWT was 325 meters (interquartile range, 96-480 m). Conclusion: Follow-up of COVID-19 patients revealed radiological abnormalities in most cured COVID-19 patients, indicating the need for more extended follow-up periods for investigating the long-term consequences of COVID-19.","PeriodicalId":13454,"journal":{"name":"Immunopathologia Persa","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2023-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47570147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Masoumeh Faramarzi, A. Khorramdel, A. Babaloo, M. Sadighi, Ali Sadaghian
Introduction: Cytokines play a prominent role in the induction of periodontal diseases. Aloe vera can ameliorate periodontal disease considering its anti-inflammatory and antibacterial effects. Objectives: This study investigated the effect of topical aloe vera gel, associated with scaling and root planing (SRP), on interleukin-1 (IL-1) and interleukin-17 (IL-17) of gingival crevicular fluid (GCF) levels in chronic periodontitis patients. Patients and Methods: This study recruited 20 patients diagnosed with moderate to severe chronic periodontitis (with probing pocket depths of ≥5 mm). The control group subjects underwent only SRP; the test group subjects underwent SRP, followed by topical aloe vera gel application. Periodontal clinical parameters, including probing depth (PD), clinical attachment level (CAL) and gingival index (GI), were determined; GCF levels of IL-1 and IL-17 were determined using the enzyme-linked immunosorbent assay (ELISA) at baseline and one month postoperatively. Results: There were significant decreases in periodontal clinical parameters in both groups compared to the baseline. The test group exhibited a significant decrease in interleukin levels compared with the control group as follows; interleukin-1 beta (IL-1β) (control; 61.78±14.54, test; 43.06±10.99 ng/mL) (P<0.001), IL-17 (control; 81.33±16.66, test; 57.04±16.26 ng/mL) (P<0.001). Conclusion: Topical aloe vera gel in combination with SRP significantly improved clinical parameters of periodontitis and decreased IL-1β and IL-17 GCF levels. Trial Registration: The trial protocol of the present study was approved by the Iranian registry of Clinical Trials (identifier: IRCT20100412003690N11; https://en.irct.ir/trial/44975; ethical code #IR.TBZMED.REC.1398.1113).
{"title":"Effect of topical aloe vera gel on gingival crevicular fluid interleukin-1 beta and interleukin-17 levels in patients with chronic periodontitis; A double-blind split-mouth randomized clinical trial","authors":"Masoumeh Faramarzi, A. Khorramdel, A. Babaloo, M. Sadighi, Ali Sadaghian","doi":"10.34172/ipp.2023.34426","DOIUrl":"https://doi.org/10.34172/ipp.2023.34426","url":null,"abstract":"Introduction: Cytokines play a prominent role in the induction of periodontal diseases. Aloe vera can ameliorate periodontal disease considering its anti-inflammatory and antibacterial effects. Objectives: This study investigated the effect of topical aloe vera gel, associated with scaling and root planing (SRP), on interleukin-1 (IL-1) and interleukin-17 (IL-17) of gingival crevicular fluid (GCF) levels in chronic periodontitis patients. Patients and Methods: This study recruited 20 patients diagnosed with moderate to severe chronic periodontitis (with probing pocket depths of ≥5 mm). The control group subjects underwent only SRP; the test group subjects underwent SRP, followed by topical aloe vera gel application. Periodontal clinical parameters, including probing depth (PD), clinical attachment level (CAL) and gingival index (GI), were determined; GCF levels of IL-1 and IL-17 were determined using the enzyme-linked immunosorbent assay (ELISA) at baseline and one month postoperatively. Results: There were significant decreases in periodontal clinical parameters in both groups compared to the baseline. The test group exhibited a significant decrease in interleukin levels compared with the control group as follows; interleukin-1 beta (IL-1β) (control; 61.78±14.54, test; 43.06±10.99 ng/mL) (P<0.001), IL-17 (control; 81.33±16.66, test; 57.04±16.26 ng/mL) (P<0.001). Conclusion: Topical aloe vera gel in combination with SRP significantly improved clinical parameters of periodontitis and decreased IL-1β and IL-17 GCF levels. Trial Registration: The trial protocol of the present study was approved by the Iranian registry of Clinical Trials (identifier: IRCT20100412003690N11; https://en.irct.ir/trial/44975; ethical code #IR.TBZMED.REC.1398.1113).","PeriodicalId":13454,"journal":{"name":"Immunopathologia Persa","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2023-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42769213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Diabetes mellitus is a metabolite disorder with parameters of high blood sugar levels. In the management of diabetes can be used the drug metformin is the gold of choice to achieve a therapeutic effect and rarely causes side effects of the drug, but it still has debate view. However, if used in excessive doses for patients with kidney disease, it will be contraindicated with side effects such as lactic acidosis. Objective: This study aims to evaluate the side effect of metformin for diabetic kidney disease (DKD) patients. Methods: This study used the Narrative Review Method that was obtained from 2011 to 2021, in the English language from PubMed, Google Scholar, and Cochrane Library. Results: Metformin is at the forefront of the treatment of type 2 diabetes mellitus (DM2). Metformin is likely to have lactic acidosis-related adverse effects in chronic kidney disease (CKD) patients, such as increased arterial lactate. Lactic acidosis is defined as an increase in arterial lactate with an indicator of more than five mmol/L and an arterial blood pH of less than 7.35. Metformin-induced lactate levels are below the parameters. DKD risk factors can be conceptually classified as several susceptibility factors, initiation factors, and developmental factors. The two most prominent risk factors are hyperglycemia and hypertension. Conclusion: Metformin can increase lactate levels in CKD patients but is still below the parameters of lactic acidosis. This study may have some weaknesses and requires further prospective research to validate the results.
{"title":"Lactic acidosis associated with metformin in patients with diabetic kidney disease; a mini-review","authors":"Fatkhu Rahman, S. Tuba","doi":"10.34172/ipp.2023.34450","DOIUrl":"https://doi.org/10.34172/ipp.2023.34450","url":null,"abstract":"Background: Diabetes mellitus is a metabolite disorder with parameters of high blood sugar levels. In the management of diabetes can be used the drug metformin is the gold of choice to achieve a therapeutic effect and rarely causes side effects of the drug, but it still has debate view. However, if used in excessive doses for patients with kidney disease, it will be contraindicated with side effects such as lactic acidosis. Objective: This study aims to evaluate the side effect of metformin for diabetic kidney disease (DKD) patients. Methods: This study used the Narrative Review Method that was obtained from 2011 to 2021, in the English language from PubMed, Google Scholar, and Cochrane Library. Results: Metformin is at the forefront of the treatment of type 2 diabetes mellitus (DM2). Metformin is likely to have lactic acidosis-related adverse effects in chronic kidney disease (CKD) patients, such as increased arterial lactate. Lactic acidosis is defined as an increase in arterial lactate with an indicator of more than five mmol/L and an arterial blood pH of less than 7.35. Metformin-induced lactate levels are below the parameters. DKD risk factors can be conceptually classified as several susceptibility factors, initiation factors, and developmental factors. The two most prominent risk factors are hyperglycemia and hypertension. Conclusion: Metformin can increase lactate levels in CKD patients but is still below the parameters of lactic acidosis. This study may have some weaknesses and requires further prospective research to validate the results.","PeriodicalId":13454,"journal":{"name":"Immunopathologia Persa","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2023-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46275992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Investigating the role of CD44 expression in the survival of colorectal cancer patients","authors":"MH. Sanei, Maryam Malekmohammad, M. Sanei","doi":"10.34172/ipp.2023.38452","DOIUrl":"https://doi.org/10.34172/ipp.2023.38452","url":null,"abstract":"<jats:p>\u0000 </jats:p>","PeriodicalId":13454,"journal":{"name":"Immunopathologia Persa","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2023-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44873340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction: Nestin plays a significant role in diagnosis, prognosis, clinical course and/or response to the treatment. Previous studies have investigated the nestin expression in melanoma, however a limited number have focused on basal cell carcinoma (BCC) and basosquamous carcinoma (BSC). Objectives: The current study aimed to investigate nestin expression in melanoma, BCC, and BSC. Materials and Methods: This cross-sectional study was conducted on 40 melanomas, 40 BCC and 40 BSC specimens. Tumor size, lesion location and stage of disease were recorded. Then, nestin staining was conducted in all the present samples, then the amount of nestin expression was assessed. Results: According to the results of this study, nestin was expressed in all melanoma specimens; while it was expressed in 15% of BSC and 25% of BCC specimens. The mean score of nestin expression in melanoma specimens (0.85 ± 2.50) was significantly higher than the BSC and BCC specimens with the means of 0.36±0.15 and 0.44±0.25 respectively (P value <0.001). However, there was no significant difference between BSC and BCC specimens in nestin expression. Additionally, in the melanoma specimens, a significant and direct relationship between nestin expression and the various stages of melanoma with the coefficient of 0.345 (P value = 0.025). Conclusion: The results of the current study showed that expression of nestin could have a good prognostic value in skin melanoma while, there is a significant relationship with its progression. However, in non-melanoma specimens, no distinction can be detected regarding the nestin expression.
{"title":"Evaluation of nestin expression in melanoma, basal cell carcinoma and basosquamous carcinoma","authors":"M. Mokhtari, Negar Safari","doi":"10.34172/ipp.2023.34431","DOIUrl":"https://doi.org/10.34172/ipp.2023.34431","url":null,"abstract":"Introduction: Nestin plays a significant role in diagnosis, prognosis, clinical course and/or response to the treatment. Previous studies have investigated the nestin expression in melanoma, however a limited number have focused on basal cell carcinoma (BCC) and basosquamous carcinoma (BSC). Objectives: The current study aimed to investigate nestin expression in melanoma, BCC, and BSC. Materials and Methods: This cross-sectional study was conducted on 40 melanomas, 40 BCC and 40 BSC specimens. Tumor size, lesion location and stage of disease were recorded. Then, nestin staining was conducted in all the present samples, then the amount of nestin expression was assessed. Results: According to the results of this study, nestin was expressed in all melanoma specimens; while it was expressed in 15% of BSC and 25% of BCC specimens. The mean score of nestin expression in melanoma specimens (0.85 ± 2.50) was significantly higher than the BSC and BCC specimens with the means of 0.36±0.15 and 0.44±0.25 respectively (P value <0.001). However, there was no significant difference between BSC and BCC specimens in nestin expression. Additionally, in the melanoma specimens, a significant and direct relationship between nestin expression and the various stages of melanoma with the coefficient of 0.345 (P value = 0.025). Conclusion: The results of the current study showed that expression of nestin could have a good prognostic value in skin melanoma while, there is a significant relationship with its progression. However, in non-melanoma specimens, no distinction can be detected regarding the nestin expression.","PeriodicalId":13454,"journal":{"name":"Immunopathologia Persa","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2023-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47651381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Mousavi, Shahin Asgari Savadjani, H. Karimzadeh, Bahram Pakzad, Mansour Salesi
Introduction: Type 2 diabetes mellitus (T2DM) increases the risk of bone fractures. Objectives: This study aimed to examine the use of trabecular bone score (TBS) and BMD to select the best diagnostic tool for osteoporosis caused by type 2 diabetes. Patients and Methods: One hundred and four patients (52 individuals with type 2 diabetes and 52 ones without diabetes) aged at most 50 years were enrolled in a cross-sectional study that was conducted with dual-energy X-ray absorptiometry (DXA) images of patients referred to Khorshid and Al-Zahra hospitals, Isfahan, Iran. Results: Lumbosacral bone mineral density (BMD) was significantly lower in the diabetic group than in the control group (0.76 versus 0.82, P=0.041). The mean lumbosacral TBS was significantly lower in the diabetic group than in the controls (1.24 versus 1.36, P=0.001). Therefore, the lumbosacral TBS provided a more reliable indicator than lumbosacral BMD to discriminate between controls and women with T2DM. Conclusion: The TBS is recommended for early diagnosis of osteoporosis in diabetic patients because of its independence from BMD-related parameters. The TBS can capture a larger portion of the bone deterioration in women with T2DM that cannot be detected using methods based solely on BMD.
2型糖尿病(T2DM)增加骨折的风险。目的:本研究旨在探讨使用骨小梁评分(TBS)和骨密度(BMD)来选择2型糖尿病所致骨质疏松的最佳诊断工具。患者和方法:104名年龄不超过50岁的患者(52名2型糖尿病患者和52名非糖尿病患者)参加了一项横断面研究，该研究采用伊朗伊斯法罕Khorshid和Al-Zahra医院患者的双能x射线吸收仪(DXA)图像进行。结果:糖尿病组腰骶骨骨密度(BMD)明显低于对照组(0.76比0.82,P=0.041)。糖尿病组腰骶部平均TBS显著低于对照组(1.24 vs 1.36, P=0.001)。因此，腰骶部TBS比腰骶部BMD提供了一个更可靠的指标来区分对照组和女性T2DM。结论:TBS独立于bmd相关参数，可用于糖尿病骨质疏松症的早期诊断。TBS可以捕捉到T2DM患者骨退化的更大一部分，而仅基于BMD的方法无法检测到。
{"title":"Evaluation of bone mineral density and trabecular bone score for diagnosis of osteoporosis in Iranian diabetic patients","authors":"M. Mousavi, Shahin Asgari Savadjani, H. Karimzadeh, Bahram Pakzad, Mansour Salesi","doi":"10.34172/ipp.2023.34434","DOIUrl":"https://doi.org/10.34172/ipp.2023.34434","url":null,"abstract":"Introduction: Type 2 diabetes mellitus (T2DM) increases the risk of bone fractures. Objectives: This study aimed to examine the use of trabecular bone score (TBS) and BMD to select the best diagnostic tool for osteoporosis caused by type 2 diabetes. Patients and Methods: One hundred and four patients (52 individuals with type 2 diabetes and 52 ones without diabetes) aged at most 50 years were enrolled in a cross-sectional study that was conducted with dual-energy X-ray absorptiometry (DXA) images of patients referred to Khorshid and Al-Zahra hospitals, Isfahan, Iran. Results: Lumbosacral bone mineral density (BMD) was significantly lower in the diabetic group than in the control group (0.76 versus 0.82, P=0.041). The mean lumbosacral TBS was significantly lower in the diabetic group than in the controls (1.24 versus 1.36, P=0.001). Therefore, the lumbosacral TBS provided a more reliable indicator than lumbosacral BMD to discriminate between controls and women with T2DM. Conclusion: The TBS is recommended for early diagnosis of osteoporosis in diabetic patients because of its independence from BMD-related parameters. The TBS can capture a larger portion of the bone deterioration in women with T2DM that cannot be detected using methods based solely on BMD.","PeriodicalId":13454,"journal":{"name":"Immunopathologia Persa","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2023-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47594873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Masood Zadkarami, Foroozan Rahimpour, A. Hardani, H. Javaherizadeh
Introduction: Recently ursodeoxycholic acid was recommended for the treatment of neonatal hyperbilirubinemia in a few studies. Objectives: This study aimed to compare ursodeoxycholic acid and phototherapy versus phototherapy in lowering the level of bilirubin in neonates who was admitted due to hyperbilirubinemia. Patients and Methods: This randomized double-blind study was carried out in the department of neonatology at the children’s medical center of Ahvaz Jundishapur of the University of Medical Sciences. Inclusion criteria were weight 2500-4200 g and exclusive breastfeeding. Gestational age between 38-41 weeks and age between 3-7 days were included. Total bilirubin between 14-20 according to Bhutani nomogram and direct bilirubin was less than 2 mg/dl was included. Exclusion criteria were ABO incompatibility, Rh incompatibility, G6PD (glucose6-phosphate dehydrogenase) deficiency, sepsis, hypothyroidism, liver problem, prematurity and newborn of diabetic mothers. A dose of 5 mg/kg per dose of ursodeoxycholic acid (UDCA) was prescribed for neonates every 12 hours. Placebo is also prescribed for other neonates. Unconjugated bilirubin was measured after 4 hours and every 12 hours till total bilirubin=12 mg/dL. The primary outcome measures were total bilirubin level four hours and every 12 hours after admission till reached 12 mg/dL. The secondary outcome measure was total bilirubin=12 mg/dL at 12-24 hours after admission and diarrhea, vomiting, skin rash or any adverse effect in the neonates who received UDCA. Neonates who underwent phototherapy and UDCA were the case group. Neonates who received phototherapy and placebo were allocated in the control group. Data were analyzed using SPSS version 16.0. Kolmogorov-Smirnov test was conducted to evaluate data distribution. Intention-to-treat analysis was used. Mann-Whitney U test was conducted for data analysis. Results: In the current study, 30 cases and 30 control were included. Discharged neonates were 96% among the UDCA group and 87% among the control group in the 1st 24 hours after admission. Among the UDCA group, 100% were discharged at the 2nd 24 hours of admission and 96% among the control. The duration of phototherapy was shorter in the case group than in the control group, however this difference had no statistical difference. Conclusion: No significant difference between neonates who underwent phototherapy and phototherapy+ UDCA in terms of duration of phototherapy and bilirubin reduction was found. Trial Registration: The trial protocol was approved by the Iranian Registry of Clinical Trials (identifier: IRCT20181003041225N1; https://en.irct.ir/trial/34272, ethical code; IR.AJUMS.REC.1397.899).
{"title":"Ursodeoxycholic acid and phototherapy versus phototherapy and placebo on neonatal indirect hyperbilirubinemia","authors":"Masood Zadkarami, Foroozan Rahimpour, A. Hardani, H. Javaherizadeh","doi":"10.34172/ipp.2023.35457","DOIUrl":"https://doi.org/10.34172/ipp.2023.35457","url":null,"abstract":"Introduction: Recently ursodeoxycholic acid was recommended for the treatment of neonatal hyperbilirubinemia in a few studies. Objectives: This study aimed to compare ursodeoxycholic acid and phototherapy versus phototherapy in lowering the level of bilirubin in neonates who was admitted due to hyperbilirubinemia. Patients and Methods: This randomized double-blind study was carried out in the department of neonatology at the children’s medical center of Ahvaz Jundishapur of the University of Medical Sciences. Inclusion criteria were weight 2500-4200 g and exclusive breastfeeding. Gestational age between 38-41 weeks and age between 3-7 days were included. Total bilirubin between 14-20 according to Bhutani nomogram and direct bilirubin was less than 2 mg/dl was included. Exclusion criteria were ABO incompatibility, Rh incompatibility, G6PD (glucose6-phosphate dehydrogenase) deficiency, sepsis, hypothyroidism, liver problem, prematurity and newborn of diabetic mothers. A dose of 5 mg/kg per dose of ursodeoxycholic acid (UDCA) was prescribed for neonates every 12 hours. Placebo is also prescribed for other neonates. Unconjugated bilirubin was measured after 4 hours and every 12 hours till total bilirubin=12 mg/dL. The primary outcome measures were total bilirubin level four hours and every 12 hours after admission till reached 12 mg/dL. The secondary outcome measure was total bilirubin=12 mg/dL at 12-24 hours after admission and diarrhea, vomiting, skin rash or any adverse effect in the neonates who received UDCA. Neonates who underwent phototherapy and UDCA were the case group. Neonates who received phototherapy and placebo were allocated in the control group. Data were analyzed using SPSS version 16.0. Kolmogorov-Smirnov test was conducted to evaluate data distribution. Intention-to-treat analysis was used. Mann-Whitney U test was conducted for data analysis. Results: In the current study, 30 cases and 30 control were included. Discharged neonates were 96% among the UDCA group and 87% among the control group in the 1st 24 hours after admission. Among the UDCA group, 100% were discharged at the 2nd 24 hours of admission and 96% among the control. The duration of phototherapy was shorter in the case group than in the control group, however this difference had no statistical difference. Conclusion: No significant difference between neonates who underwent phototherapy and phototherapy+ UDCA in terms of duration of phototherapy and bilirubin reduction was found. Trial Registration: The trial protocol was approved by the Iranian Registry of Clinical Trials (identifier: IRCT20181003041225N1; https://en.irct.ir/trial/34272, ethical code; IR.AJUMS.REC.1397.899).","PeriodicalId":13454,"journal":{"name":"Immunopathologia Persa","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2023-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44480179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：